<DOC>
	<DOCNO>NCT01252017</DOCNO>
	<brief_summary>The purpose study determine whether nilotinib effective prophylaxis treatment CMV reactivation allo-HSCT patient .</brief_summary>
	<brief_title>Nilotinib Cytomegalovirus Prophylaxis Treatment After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>The purpose study determine whether nilotinib effective prophylaxis treatment CMV reactivation allo-HSCT patient . Prophylaxis Part : patient treat nilotinib hemogram engraftment prevent CMV reactivation Salvage Part : patient intractable CMV reactivation gancyclovir therapy treat nilotinib</detailed_description>
	<criteria>Part A : Adult patient receive alloHSCT Performance status ECOG 02 Patients CMV reactivation ( define plasma CMV DNA copy number 1000 copy numbers/ml QuantitativePCR ) alloHSCT . Patients CMV reactivation uncontrollable conventional first line agent ( ganciclovir ) 2 week , patient intolerable ganciclovir treatment . Part B Adult patient receive alloHSCT Performance status ECOG 02 Either patient his/her donor CMVIgG test positive Patients posttransplantation engraftment : stable myeloid engraftment ( absolute neutrophil count 500/mm3 ) least 3 consecutive day , stable megakaryocyte engraftment ( platelet count 20k/uL ) least 3 consecutive day . Patient CMV reactivation enrollment : negative ( undetectable ) plasma CMV DNA QuantitativePCR assay blood collect within 7 day Patients without previous current exposure prophylactic therapeutic drug CMV reactivation Patients renal insufficiency : serum creatinine &gt; 2.5 mg/dL , Patients significant electrolyte deficiency suitable supplement : [ K ] &lt; 3.0mmol/L , [ Ca ] &lt; 2.0 mmol/L ( correct ) , [ Mg ] &lt; 0.6 mmol/L . Patients hepatic dysfunction : alkaline phosphatase â‰¥2.5 time upper normal limit normal range ( ULN ) ; serum alanine aspartate aminotransferase level &gt; 5 time ULN ; serum total bilirubin &gt; 3 mg/dL Patients serum amylase lipase &gt; 1.5 x ULN Patients history HIV infection Patients unstable medical condition history serious/significant medical disease deem appropriate include study judge investigator Females patient pregnant breastfeed Female patient childbearing potential use reliable appropriate contraception method ( ) Patients life expectancy , judge investigator , less 3 month Patients , judge investigator , contraindication nilotinib administration , prolong QTc , concurrent usage drug posse possible severe drugdrug interaction nilotinib , severe adverse effect previous exposure nilotinib Patients swallow capsule . Patients unwilling unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>